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In silico re-engineering of a neurotransmitter
to activate KCNQ potassium channels in an
isoform-speciﬁc manner
Rían W. Manville1 & Geoffrey W. Abbott1*
Voltage-gated potassium (Kv) channel dysfunction causes a variety of inherited disorders,
but developing small molecules that activate Kv channels has proven challenging. We
recently discovered that the inhibitory neurotransmitter γ-aminobutyric acid (GABA) directly
activates Kv channels KCNQ3 and KCNQ5. Here, ﬁnding that inhibitory neurotransmitter
glycine does not activate KCNQs, we re-engineered it in silico to introduce predicted KCNQ-
opening properties, screened by in silico docking, then validated the hits in vitro. Attaching a
ﬂuorophenyl ring to glycine optimized its electrostatic potential, converting it to a low-nM
afﬁnity KCNQ channel activator. Repositioning the phenyl ring ﬂuorine and/or adding a
methylsulfonyl group increased the efﬁcacy of the re-engineered glycines and switched their
target KCNQs. Combining KCNQ2- and KCNQ3-speciﬁc glycine derivatives synergistically
potentiated KCNQ2/3 activation by exploiting heteromeric channel composition. Thus, in
silico optimization and docking, combined with functional screening of only three compounds,
facilitated re-engineering of glycine to develop several potent KCNQ activators.
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Voltage-gated potassium (Kv) channel pore-forming αsubunits are generated by a numerous and diverse genefamily comprising 40 members in the human genome,
separated into 12 subfamilies. Native Kv channels also contain
regulatory subunits that shape their functional properties and
further expand their diversity and functional repertoire. Kv
channels are essential for a wide range of physiological processes,
and in many cases little functional redundancy is observed even
between seemingly closely related isoforms. Accordingly, dis-
ruption of speciﬁc Kv channel α or β subunits by inherited or
sporadic human gene variants (or gene deletion in mice) is
associated with a variety of disease syndromes, many of which are
severe and often lethal1.
Despite in-depth knowledge of many of the physiological
functions of speciﬁc Kv channels, and of the pathophysiological
consequences of their disruption, therapeutic pharmacological
targeting of the channels has been challenging. One of the reasons
for this is that a great many Kv channel-linked disorders, or
channelopathies, arise from loss of function. Direct correction of
these requires, therefore, channel openers—a more difﬁcult task
than developing channel inhibitors or blockers.
One of the best known Kv channel openers is the drug reti-
gabine (ezogabine). Retigabine activates neuronal KCNQ chan-
nels by negative-shifting their voltage dependence of activation2,3.
Heteromeric KCNQ2/3 channels are particularly important in
generating the muscarinic-inhibited M-current, a background Kv
current that acts as a gatekeeper to limit aberrant neuronal
ﬁring4,5. Retigabine was the ﬁrst Kv channel opener to reach
the clinic, but was withdrawn in 2017 because of off-target side
effects—it turns the sclera and skin blue6. However, it is effective
at opening KCNQ2/3 channels and was clinically useful, mostly
as an add-on therapy, in epilepsy. Since the development of
retigabine, a new syndrome was recognized, termed KCNQ2
encephalopathy7. Caused primarily by sporadic, KCNQ2 loss-of-
function mutations (as carriers tend not to reproduce), this dis-
ease is notable for severe developmental delays in addition to
epilepsy. Clearly, new activators of KCNQ2 and many other Kv
channels are needed, and this need will be acknowledged further
as other Kv channelopathies are identiﬁed.
We recently made the surprising discovery that the pre-
dominant inhibitory neurotransmitter γ-aminobutyric acid
(GABA) binds in a similar binding pocket to that of retigabine,
and activates KCNQ3, KCNQ5, and KCNQ2/3 channels8. We
also found that other metabolites, GABA analogs, and phyto-
chemicals bind to a similar site, the majority also opening KCNQ
channels by favoring their activation at more hyperpolarized
membrane potentials8–10. KCNQ channels, and possibly other Kv
channels, thereby possess a binding pocket that accommodates
numerous types of small-molecule activators.
Glycine, which is structurally related to GABA, is also an
inhibitory neurotransmitter. Here, after ﬁnding that glycine does
not activate KCNQ channels, we re-engineered the glycine
structure in silico to introduce known properties of KCNQ acti-
vators, and tested candidates using docking simulations. With
minimal real-world functional screening, this led to discovery of a
series of potent KCNQ channel openers, including a pair of
activators that leverage isoform preferences to synergistically
activate KCNQ2/3.
Results
In silico re-engineering glycine to activate KCNQ channels.
Synthetic anticonvulsants such as retigabine possess negative
electrostatic surface potential near their carbonyl groups, a
property found to be important for their activation of KCNQ2/3
channels11 (Fig. 1a). GABA possesses this same chemical
property and also activates KCNQ2/3 channels8 (Fig. 1b). Here,
we show that glycine, the next most prominent inhibitory neu-
rotransmitter, exhibits relatively weaker negative electrostatic
surface potential that is not well centered at its carbonyl oxygen
(Fig. 1c), nor does it activate KCNQ2/3, unlike GABA and reti-
gabine, which activated KCNQ2/3 channels here with EC50 values
of 220 ± 160 nM and 6.9 ± 0.34 µM, respectively (Fig. 1d, e)
(Supplementary Data 1, Tables 1–3). We hypothesized that re-
engineering glycine to center surface negative electrostatic
potential on its carbonyl oxygen would endow it with the cap-
ability to open KCNQ2/3. We therefore next mapped in silico the
surface charge of a number of glycine derivatives.
In the simplest derivatives, surface negative potential was still
skewed away from the carbonyl (Fig. 1f). In several more complex
structures, including iminodiacetic acid glycine derivatives and N-
[Bis(methylthiomethylene]glycine, the negative potential was
skewed and/or partially hidden; in N,N-Bis(phosphonomethyl)
glycine the negative potential was centered around a phosphate
oxygen rather than the glycine carbonyl oxygen (Fig. 1g).
However, replacing one of the glycine amino group hydrogens
with a substituted phenyl ring centered a strong negative surface
potential on the glycine carbonyl oxygen; 4-(ﬂuorophenyl)glycine
(4FPG) resulted in a single center of electronegative surface
charge, while 4-(hydroxyphenyl)glycine also exhibited a second
center of electronegative surface potential at the phenyl hydroxyl
group (Fig. 1h).
For the second in silico prediction phase, using SwissDock we
performed unbiased docking prediction analysis of the glycine
derivatives to a KCNQ1-KCNQ3 chimeric model8 based on the
recent cryo-EM derived KCNQ1 structure12. We were especially
interested in binding in the pocket lined on one side by the S5
tryptophan (W265 on KCNQ3) that is important for retigabine
and GABA binding8,13, and on the other side by the S4-S5 linker-
proximal arginine at the foot of S4 (R242 in KCNQ3) that is
required for binding of phytochemicals such as mallotoxin to
KCNQ channels14 and mutation of which in KCNQ2 causes
benign familial neonatal convulsions15 (Fig. 2a–c). As expected
from its chemical properties and lack of effects on KCNQ2/3,
glycine failed to dock (Fig. 2d). In contrast, 4FPG docked in the
binding pocket (red oval, Fig. 2e) whereas other glycine
derivatives did not (black ovals, Fig. 2e). The docking position
of 4FPG was closer to the S4-5 arginine (purple) than to the S5
tryptophan (red) (Fig. 2f). Surface electrostatic potential plotting
shows that 4FPG possesses negative charge (red) close to its
carbonyl oxygen (Fig. 2g). In the majority of poses, 4FPG was
positioned lengthways between the S5 W and the S4-5 R with
either the ﬂuorine or the carbonyl oxygen in 4FPG proximal to
the S5 tryptophan (Fig. 2h).
4FPG isoform-selectively activates KCNQ channels. We next
validated the in silico predictions using two-electrode voltage
clamp of homomeric neuronal KCNQ2-5 channel isoforms
expressed in Xenopus laevis oocytes. By quantifying the hyper-
polarizing shift in voltage dependence of KCNQ channel activa-
tion (ΔV0.5act) versus [4FPG], we discovered that, as predicted,
4FPG is a KCNQ channel opener. 4FPG most potently activated
(i.e., negative-shifted the voltage dependence of activation of)
KCNQ4 (EC50= 49 ± 12 nM), followed by KCNQ2 (EC50= 69 ±
31 nM) and KCNQ1 (EC50= 90 ± 20 nM), and had no effects on
KCNQ3* or KCNQ5 (Fig. 2i–k) (Supplementary Data 1,
Tables 4–8). As in previous studies8,10, we used the A315T
KCNQ3 mutant (KCNQ3*) that ensures large enough currents to
accurately quantify voltage dependence and pharmacology of
homomeric KCNQ316. 4FPG speeded KCNQ2 and KCNQ4
activation and slowed their deactivation, suggesting that it opens
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these channels by stabilizing an open state and/or destabilizing a
closed state. In contrast, 4FPG slowed KCNQ1 deactivation but
did not speed its activation, suggesting 4FPG may solely desta-
bilize the closed state in KCNQ1 (Fig. 2k, l) (Supplementary
Data 1, Tables 9–12). This is potentially of mechanistic interest, as
KCNQ1 lacks the S5 W required for activation by retigabine, yet
its activity is still potentiated by 4FPG. The data suggest that the
S5 W may be important for effects on the activated state, yet is
not required for effects on the deactivated state, at least in
KCNQ1. The preference for KCNQ4 activation was in contrast to
GABA and gabapentin, which we previously found8 to each
activate only KCNQ3 and KCNQ5, and to retigabine which
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Fig. 1 In silico engineering predicted KCNQ-opening properties into glycine. a Retigabine structure, electrostatic surface potentials (red, electron-dense;
blue, electron-poor; green, neutral) and an overlay of the two, all calculated and plotted using Jmol. Arrow carbonyl oxygen. b GABA, parameters as in
(a). c Glycine, parameters as in (a). d Mean traces showing effects of GABA, glycine and retigabine on KCNQ2/3 channels expressed in Xenopus oocytes
(n= 4–6). Voltage protocol (inset) was used for all TEVC recordings in this study unless otherwise indicated. e KCNQ2/3 dose response to glycine, GABA
and retigabine, quantiﬁed from recordings as in (d) as the shift in voltage dependence of activation (ΔV0.5act) measured from the tail current. Error bars
indicate SEM; n= 4–6. f Structures and surface potential plots (as in (a)) for the simple glycine derivatives indicated; arrows, carbonyl oxygen. g Structures
and surface potential plots (as in a) for the double-carbonyl or branched glycine derivatives indicated; arrows, carbonyl oxygen. h Structures and surface
potential plots (as in (a)) for the glycine derivatives bearing a phenyl ring; arrows indicate carbonyl group
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favors KCNQ3 and activates KCNQ2, KCNQ4 and KCNQ5 to a
lesser extent, and does not activate KCNQ18,9,17. Thus, in con-
trast to 4FPG, here glycine and GABA were unable to open
KCNQ2 and KCNQ4 homomers (Fig. 2m) (Supplementary
Data 1, Tables 13–16).
Subtle modiﬁcations to 4FPG create derivatives with altered
KCNQ isoform selectivity. KCNQ1 and KCNQ4 are expressed in
multiple tissues (KCNQ4 in the auditory system and vasculature,
KCNQ1 in the cardiovascular system and multiple epithelia) and
their activation might cause unwanted off-target effects if one
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were instead intending to target KCNQ2 in epilepsy, for example.
We therefore further re-engineered 4FPG in silico, creating sev-
eral single-halide glycine derivatives, all of which exhibited
negative electrostatic surface potential close to a carbonyl oxygen
(Fig. 3a–c). Interestingly, only those that contained a
ﬂuorophenyl ring concentrated negative surface potential at the
native glycine carbonyl and were predicted to dock in the
KCNQ1-KCNQ3 chimeric model. In addition to 4FPG these were
2-(ﬂuorophenyl)glycine (2FPG) and N-(ﬂuorophenyl)-N-
(methylsulfonyl)glycine (3FMSG). Those that centered negative
Fig. 2 In silico prediction and in vitro validation of a KCNQ-activating glycine derivative. All error bars indicate SEM. a Chimeric KCNQ1/KCNQ3 structural
model (red, KCNQ3-W265). b Topological representation of KCNQ channel showing two of the four subunits, without domain swapping for clarity.
Pentagon, approximate position of KCNQ3-W265; VSD, voltage sensing domain. c Close-up extracellular view of KCNQ1/KCNQ3 structural model (red,
KCNQ3-W265). d Docking result showing predicted lack of binding of glycine to the KCNQ1/KCNQ3 structural model. Red, KCNQ3-W265; black oval
highlights lack of glycine binding in the typical binding zone for GABA and its metabolites and analogs. e Docking results for various glycine derivatives
illustrated in Fig. 1 showing predicted binding of 4FPG within the GABA binding pocket (highlighted by red oval) but not of the other molecules (black
ovals). All predicted binding conﬁgurations shown overlaid for each molecule. f Close-up of predicted binding poses of 4FPG within the GABA binding
pocket. g Surface electrostatic potential plot of 4FPG. h Comparison of two different predicted orientations of 4FPG within the KCNQ binding pocket, as
predicted by SwissDock. i 4FPG dose responses for homomeric KCNQ1, 2, 3*, 4, and 5 channels expressed in oocytes, quantiﬁed as shift in the voltage
dependence of channel activation (ΔV0.5act); n= 4–6. j Mean traces showing effects of 4FPG (30 µM) on KCNQ1, KCNQ2 and KCNQ4; n= 4–6. k Effects
of 4FPG (30 µM) on KCNQ1, KCNQ and KCN raw and normalized (G/Gmax) tail current, calculated from traces as in panel j; n= 4–6. l Effects of 4FPG
(30 µM) on KCNQ1, KCNQ2, and KCNQ4 activation (act) and deactivation (Deact) rates, ﬁtted as a single exponential function (τ); n= 4–6. m 4FPG dose
responses for KCNQ2 and KCNQ4 compared to those of glycine and GABA, quantiﬁed as shift in voltage dependence of activation (ΔV0.5act); n= 5–6
a
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Fig. 3 In silico prediction of 4FPG-related KCNQ-activating glycine derivatives. a Chemical properties of 4FPG versus 2FPG: structure, electrostatic surface
potentials (red, electron-dense; blue, electron-poor; green, neutral) and an overlay of the two, all calculated and plotted using Jmol. Arrows, native
glycine carbonyl. b, c Chemical properties of 4FPG-related glycine derivatives, parameters as in (a). Arrows, non-native glycine carbonyls for N-
(ﬂuoroacetyl)glycine and N-(Chloroacetyl)glycine; native glycine carbonyl for 3FMSG. d Docking results showing predicted binding (red ovals) or lack
thereof (black ovals) of the compounds in (a–c) to the GABA binding pocket in the KCNQ1/KCNQ3 structural model. Red side-chain, KCNQ3-W265.
e Docking results showing predicted binding (red ovals) of three different conformational forms of 2FPG to the GABA binding pocket in the KCNQ1/
KCNQ3 structural model. Red side-chain, KCNQ3-W265. f Docking results showing predicted binding (red oval) or lack thereof (black ovals) of three
different conformational forms of 4FPG to the GABA binding pocket in the KCNQ1/KCNQ3 structural model. Red side-chain, KCNQ3-W265
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surface potential at the halide-proximal carbonyl and lacked the
phenyl group (N-(ﬂuoroacetyl)glycine and N-(chloroacetyl)gly-
cine) did not dock (Fig. 3d).
The most closely related glycine derivative to 4FPG was 2-
(ﬂuorophenyl)glycine (2FPG), the only difference being the
ﬂuorine position on the phenyl ring. 4FPG and 2FPG are each
represented in several conformations on the Zinc database
(http://zinc.docking.org/) used for ligand selection, and so we
compared docking of all conformations. All three 2FPG
conformations docked primarily to the known binding pocket
(Fig. 3e) whereas 4FPG showed more docking heterogeneity and
two of three of its conformations did not dock in the
neurotransmitter binding pocket (Fig. 3f). This suggested 4FPG
and 2FPG might have different KCNQ opening characteristics,
which we tested next.
Strikingly, 2FPG was a potent KCNQ2 isoform-selective
opener (EC50= 322 ± 139 nM) with negligible effects on KCNQ1,
3*, 4, or 5 (Fig. 4a, b) (Supplementary Data 1, Tables 17–21). The
KCNQ2 activation by 2FPG was in contrast to the non-KCNQ2
activating GABA (as we previously reported8) and glycine
(Fig. 4c). The loss of KCNQ4 opening activity, in contrast to
4FPG, was remarkable given the small differences in the 2FPG
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Fig. 4 KCNQ isoform-speciﬁc activation by ﬂuorinated glycine derivatives. All error bars indicate SEM. aMean traces showing effects of 2FPG (100 µM) on
KCNQ2 (n= 5). b 2FPG dose responses for homomeric KCNQ1, 2, 3*, 4, and 5, quantiﬁed as shift in the voltage dependence of channel activation
(ΔV0.5act) calculated from the tail current using recordings as in panel (a); n= 5. c 2FPG dose response for KCNQ2 compared to those of glycine and
GABA, quantiﬁed as current fold-change at −60mV; n= 5–6. d Comparison of 4FPG and 2FPG structures showing the change in ﬂuorine position (arrow).
e Effects of 2FPG (100 µM) on KCNQ2 raw tail currents and normalized tail current (G/Gmax); n= 5. f Effects of 2FPG (100 µM) on KCNQ2 activation and
deactivation rates, ﬁtted as a single exponential function (τ); n= 5. # P < 0.01. g Mean traces showing effects of 3FMSG (100 µM) on KCNQ3* (n= 7). h
3FMSG (glycine carbonyl highlighted with arrow) dose responses for homomeric KCNQ1, 2, 3*, 4, and 5 channels quantiﬁed as ΔV0.5act measured from the
tail currents from traces as in (g); n= 4–7. i 3FMSG dose response for KCNQ3* compared to those of glycine and GABA, quantiﬁed as ΔV0.5act; n= 5–7. j
3FMSG dose response for KCNQ5 compared to that of glycine, quantiﬁed as current fold-change at −60 mV; n= 4–5. k Effects of 3FMSG (100 µM) on
KCNQ3* raw tail current and normalized tail current (G/Gmax); n= 7. l Effects of 3FMSG (100 µM) on KCNQ3* activation and deactivation rates, ﬁtted as
a single exponential function (τ); n= 7. m Mean traces showing effects of 3FMSG (100 µM) on KCNQ5 (n= 5). n Effects of 3FMSG (100 µM) on KCNQ5
raw tail currents and normalized tail current (G/Gmax) measured from traces as in panel m; n= 5. o Effects of 3FMSG (100 µM) on KCNQ5 activation
rate, ﬁtted as a single exponential function (τ); n= 5. # P < 0.05
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and 4FPG structures (Fig. 4d). 2FPG negative-shifted the voltage
dependence of KCNQ2 activation but also increased KCNQ2
currents at more depolarized potentials (Fig. 4b, e) and speeded
KCNQ2 activation and slowed deactivation as for 4FPG (Fig. 4f)
(Supplementary Data 1, Tables 22 and 23).
3FMSG exhibited still different selectivity, activating KCNQ3*
most potently (EC50= 18 ± 12 nM) followed by KCNQ5 (EC50=
171 ± 112 nM), with negligible or much less potent effects on
KCNQ1, KCNQ2 and KCNQ4 (Fig. 4g, h). In contrast, glycine
had no effects on homomeric KCNQ3* or KCNQ5 (Fig. 4i, j)
(Supplementary Data 1, Tables 24–31). 3FMSG negative-shifted
the activation voltage dependence of KCNQ3* and also increased
current at positive voltages (Fig. 4k), speeded activation and
slowed deactivation (Fig. 4l). 3FMSG exerted similar effects on
KCNQ5 and in addition was more effective at increasing KCNQ5
current compared to KCNQ3* current at positive potentials
(Fig. 4m–o) (Supplementary Data 1, Tables 32–34).
3FMSG inhibits glycine receptor GLRA1. We next tested whe-
ther the glycine derivatives 2FPG and 3FMSG modulated the
canonical glycine receptor, GLRA1. Neither compound activated
GLRA1 at 1 mM, in contrast to glycine (1 mM) (Fig. 5a). How-
ever, 3FMSG but not 2FPG (each at 100 µM) partially inhibited
the activation of GLRA1 by 1 mM glycine (Fig. 5b). The degree of
GLRA1 inhibition by 3FMSG was similar (~40%) whether or not
3FMSG alone was applied immediately before co-application of
glycine with 3FMSG (Fig. 5c, d). Interestingly, co-application of
3FMSG also reduced the degree of desensitization observed
during glycine activation of GLRA1 (Fig. 5b, c). Thus, 3FMSG but
not 2FPG retains its ability to bind to a canonical glycine
receptor, but acts as an inhibitor rather than an activator. The
40% inhibition by 3FMSG at 100 µM suggests a lower potency
than its submicromolar activating effects on KCNQ3* and
KCNQ5, although the comparison is difﬁcult to quantify as
3FMSG may be competing with glycine, assuming it binds to the
same site, on GLRA1.
Glycine derivatives differentially activate KCNQ2/3 channels.
As KCNQ2/3 heteromers are the predominant neuronal KCNQ
isoform, we tested their sensitivity to the glycine derivatives. All
three derivatives activated KCNQ2/3 (Fig. 6a, b), with 2FPG and
3FMSG the more efﬁcacious at opening KCNQ2/3 and at
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KCNQ2/3-dependently shifting the resting membrane potential
(Fig. 6c). All three compounds were much more potent than
retigabine (2FPG, EC50= 184 ± 15 nM; 3FMSG, EC50= 51 ± 21
nM; 4FPG, EC50= 61 ± 42 nM; retigabine, EC50= 6.87 ± 0.34
µM) although none came close to matching its efﬁcacy upon
KCNQ2/3 (Fig. 6d, e) (Supplementary Data 1, Tables 35–37). As
we observed for homomeric channels, 2FPG and 3FMSG speeded
KCNQ2/3 activation and slowed its deactivation (Fig. 6f, g)
(Supplementary Data 1, Tables 38–41).
2FPG and 3FMSG occupy the KCNQ neurotransmitter bind-
ing pocket. Docking poses predicted that 2FPG binds between the
S5 tryptophan (W236 in KCNQ2) and the arginine at the foot of
S4 (R213 in KCNQ2) (Fig. 7a, b). Wash-in and washout experi-
ments revealed immediate onset of 2FPG effects on KCNQ2/3
channels upon commencing wash-in, and immediate reduction in
current upon commencing washout; glycine as expected had no
effect (Fig. 7c). Fitting with a single exponential function the
effects on KCNQ2/3 current during 2FPG wash-in and washout
revealed tau values of 16 ± 3 s and 42 ± 9 s, respectively (Fig. 7d).
These time-courses are not compatible with 2FPG having to cross
the plasma membrane to access its binding site from the intra-
cellular face of the plasma membrane, which would typically not
give rise to immediate onset of effects during wash-in and would
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require several minutes to wash out. Instead, together with the
docking predictions, the wash kinetics are more consistent with
2FPG accessing a deep binding site via the outer face of the
membrane. We next tested the docking predictions in vitro using
site-directed mutagenesis and TEVC. Mutating the S4-juxtaposed
arginines in KCNQ2/3, we found that 2FPG required KCNQ2-
R213 but not KCNQ3-R242 (Fig. 7e, f). Similarly, KCNQ2/
3 sensitivity to 2FPG was much more sensitive to mutation of
KCNQ2-W236 than mutation of KCNQ3-W265 (Fig. 7g, h; dose
responses in Fig. 7i, j). The dependence of 2FPG on the KCNQ2,
but not KCNQ3, W and R residues in the previously discovered
retigabine and GABA binding pocket8,13 reﬂected data from the
homomeric channels showing KCNQ2 but not KCNQ3 sensitivity
to 2FPG (Fig. 4) (Supplementary Data 1, Tables 42–47).
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3FMSG also docked in silico between the S5 tryptophan (W265
in KCNQ3) and the arginine at the foot of S4 (R242 in KCNQ3)
(Fig. 8a, b). Wash-in and wash-out experiments were again
consistent with accessing a deep binding site from the
extracellular face, with immediate onset of effects upon
commencing wash-in or washout (Fig. 8c), and tau values of
15 ± 3 s for wash-in and 39 ± 10 s for washout (Fig. 8d). In
contrast to data for 2FPG, but as expected from the 3FMSG
sensitivity of KCNQ3 (Fig. 4), 3FMSG was more sensitive to
mutation of KCNQ3-R242 than KCNQ2-R213, although mutat-
ing to alanine both the KCNQ2 and KCNQ3 equivalent arginines
(RA/RA) produced a larger reduction in sensitivity (Fig. 8e, f).
More deﬁnitively, 3FMSG sensitivity was dependent on KCNQ3-
W265 but independent of KCNQ2-W236 (Fig. 8g, h; dose
responses in Fig. 8i, j) (Supplementary Data 1, Tables 48–53).
To further validate these ﬁndings, we next compared GABA
and glycine binding to KCNQ2/3 channels. As we previously
found8, tritiated GABA bound to wild-type KCNQ2/3. In
contrast, tritiated glycine did not. Accordingly, cold glycine did
not inhibit GABA binding to wild-type KCNQ2/3 (Supplemen-
tary Fig. 1a). Next, we found that the RA/RA mutation in
KCNQ2/3 almost eliminated GABA binding (Supplementary
Fig. 1b). Following the binding experiments with functional
studies, we found that the RA/RA mutation eliminated activation
of KCNQ2/3 by GABA, even at 1 mM (Supplementary Fig. 1c–e;
(Supplementary Data 1, Table 54). These data support the validity
of the in silico screening, which predicted that glycine would not
bind (Fig. 2). In addition, the data expand our knowledge of the
GABA binding site in KCNQ channels, indicating that in
addition to the S5 Trp, the S4–5 Arg is also inﬂuential both in
GABA binding and in the functional effects of GABA, as our data
in Figs 7 and 8 suggest for 2FPG and 3FMSG. As GABA is
thought to not cross the membrane (without active transport), the
data lend weight to the idea that small molecules can access, from
the extracellular face, a deep binding site within KCNQ channels
that includes the S5 Trp and includes and/or is inﬂuenced by the
S4-5 Arg.
We also studied the inﬂuence on 2FPG and 3FMSG effects of
mutations in KCNQ2 and KCNQ3* homomers. Interestingly,
KCNQ2-R213A channels exhibited increased 2FPG sensitivity
compared to that of wild-type KCNQ2 (shifting the EC50 ﬁvefold,
from 322 ± 139 nM to 57 ± 20 nM and marginally increasing the
efﬁcacy). This result is important as it provides further support
for the idea that mutating the S4-5 Arg does not simply remove
the ability of KCNQ2 activation to be modulated. Rather, it
suggests contribution (either directly or indirectly) to a binding
site that in a small-molecule speciﬁc manner can be damaged or
augmented by mutating the S4-5 arginine to alanine. Conversely,
KCNQ2-W236L channels were insensitive to 2FPG (Supplemen-
tary Fig. 2a–c; Supplementary Data 1, Tables 55, 56). KCNQ3*
sensitivity to 3FMSG was reduced 44-fold (EC50 shifted from 18
± 12 to 787 ± 80 nM) by the W265L mutation, and maximal
efﬁcacy reduced by half (Supplementary Fig. 2d, e; Supplementary
Data 1, Table 57), reafﬁrming the importance of W265L in the
effects of 3FMSG. KCNQ3*-R242 was nonfunctional and was
awakened neither by 3FMSG nor retigabine (Supplementary
Fig. 2f), a result that neither supports nor detracts from the
premise of the S4-5 Arg inﬂuencing or participating in the small
molecule binding pocket. Overall, the results further highlight the
inﬂuence of the S5 Trp and the S4-5 Arg on modulation by 2FPG
and 3FMSG.
2FPG and 3FMSG KCNQ isoform selectivity arises primarily
from functional selectivity. To examine the mechanism of
KCNQ isoform selectivity among glycine derivatives, we ﬁrst
assessed the combined effects of 2FPG and 3FMSG on homo-
meric KCNQ2 and KCNQ3 channels. A tenfold excess of 3FMSG
(100 µM) subtly reduced the efﬁcacy of 2FPG (10 µM) with
respect to KCNQ2 activation by shifting the voltage dependence
of 2FPG action such that efﬁcacy at −40 mV was greatly reduced
(although activation was still sufﬁcient to hyperpolarize the
oocyte membrane potential because effects were greater at more
negative membrane potentials). In contrast, a tenfold excess of
2FPG (100 µM) did not alter the effects of 3FMSG (10 µM) on
KCNQ3* activation at any membrane potential (Fig. 9a–d).
We next used a radioligand binding assay to quantify tritiated
GABA binding to homomeric KCNQ2 and KCNQ3* channels
expressed in oocytes. As we previously found8, GABA bound to
both KCNQ2 and KCNQ3 (Fig. 9e, f). Strikingly, 2FPG and
3FMSG (100 µM) were each able to compete out GABA binding
to both KCNQ2 and KCNQ3*. Furthermore, while 3FMSG and
2FPG were equally able to outcompete GABA for KCNQ2
binding, 2FPG was not as effective as 3FMSG at outcompeting
GABA for KCNQ3* binding. Together with the results in
Fig. 9a–c, these data show that 2FPG and 3FMSG each bind to
both KCNQ2 and KCNQ3*, to a site similar to or impinging
(directly or allosterically) upon the GABA binding site. The data
also suggest that while 2FPG has a higher binding afﬁnity than
3FMSG for KCNQ2 (and the reverse is true for KCNQ3*),
3FMSG has a higher binding afﬁnity for KCNQ2 than 2FPG does
for KCNQ3*.
As each compound can bind to both KCNQ isoforms, isoform
selectivity must arise predominantly from functional selectivity,
not binding selectivity. There are clear binding preferences,
otherwise a tenfold excess of the non-activating compound would
greatly reduce the efﬁcacy of the activating compound, and that
did not occur (Fig. 9a–c). However, these preferences are not
enough to explain the isoform selectivity shown in Fig. 4, i.e., a
lack of functional effects of 2FPG on KCNQ3*, and 3FMSG on
KCNQ2, even at high concentrations. Consistent with functional
selectivity, using measurements of ion permeability series we
found that 2FPG induces an increase in relative Na+ permeability
(compared to that of K+) in KCNQ2 but not KCNQ3*, whereas
3FMSG induces a similar increase in relative Na+ permeability of
KCNQ3* but not KCNQ2 (Fig. 9g–i; Supplementary Data 1,
Fig. 7 2FPG activation of KCNQ2/3 requires KCNQ2 R213 and W236. All error bars indicate SEM. a 2FPG structure and electrostatic surface potential map.
b SwissDock result showing predicted binding of 2FPG to a chimeric KCNQ1-KCNQ3 model, with close-up of boxed region. c Representative trace showing
effects at −60mV on KCNQ2/3 current expressed in oocytes during wash-in and/or washout of 1 mM glycine or 100 µM 2FPG. d Mean time course of
current increase and decrease during wash-in and washout respectively of 2FPG (100 µM) expressed as the tau of a single exponential function, quantiﬁed
from traces as in panel (c), n= 3 oocytes (two wash-in/out cycles per oocyte, values averaged for each oocyte). e, f Mean traces (e) and tail current-
voltage relationships (f) for wild-type and arginine-mutant KCNQ2/3 channels traces as indicated in the absence (Control) or presence of 100 µM 2FPG.
RA/RA, KCNQ2-R213A/KCNQ3-R242A; n= 5. g, h Mean traces (g) and tail current-voltage relationships (h) for wild-type and tryptophan-mutant
KCNQ2/3 channels traces as indicated in the absence (Control) or presence of 100 µM 2FPG. WL/WL, KCNQ2-W236L/KCNQ3-W265L; n= 5. i 2FPG
dose responses of wild-type and arginine-mutant KCNQ2/3 channels as in e, f, quantiﬁed as shift in voltage dependence of activation (ΔV0.5act); n= 5. j
2FPG dose responses of wild-type and tryptophan-mutant KCNQ2/3 channels as in (g, h), quantiﬁed as shift in voltage dependence of activation
(ΔV0.5act); n= 5
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Tables 58, 59). The increase in the relative Na+ permeability
induced only by the correct compound/KCNQ isoform pairing
suggested a conformational shift in the pore associated with
channel activation. We previously observed a similar shift when
KCNQ isoforms co-assembled via their pore domain with the
SMIT1 myo-inositol transporter, which also negative-shifts the
voltage dependence of KCNQ2 and KCNQ2/3 channels18.
2FPG and 3FMSG synergistically activate KCNQ2/3 channels.
As 2FPG and 3FMSG preferentially activate different KCNQ2/3
channel subunits (KCNQ2 and KCNQ3, respectively) we tested
their ability to synergistically activate KCNQ2/3 by leveraging
their isoform preferences. We used equal concentrations of each
compound to avoid possible competition for the same-isoform
binding site (see Fig. 9) and to instead leverage their binding
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preferences (2FPG for KCNQ2; 3FMSG for KCNQ3). As dis-
cussed above, the binding preferences are not the primary
mechanism underlying isoform selectivity of effects (selectivity
that persists even at high concentrations), but based on data
herein (Fig. 9a, b) would be predicted to permit synergy as they
could favor KCNQ2 binding to 2FPG, and 3FMSG binding to
KCNQ3, within KCNQ2/3 complexes. Accordingly, 2FPG and
3FMSG combined to potentiate KCNQ2/3 activity more than
each compound alone (each at 10 µM) (Fig. 10a–d). Quantifying
current fold-increase (Fig. 10e) revealed that the drugs indeed
synergistically activated KCNQ2/3 compared to either compound
alone, also resulting in robust shifts in resting membrane
potential (Fig. 10f), and robust speeding of KCNQ2/3 activation
and slowing of deactivation (Fig. 10g) (Supplementary Data 1,
Tables 60–62).
Investigating the synergy further, we dropped the concentra-
tions to 1 µM each of 2FPG and 3FMSG and still observed
synergy for KCNQ2/3 activation, increasing to a 40-fold increase
Fig. 8 3FMSG activation of KCNQ2/3 requires KCNQ3 R242 and W265. All error bars indicate SEM. a 3FMSG structure and electrostatic surface potential
map. b SwissDock result showing predicted binding of 3FMSG to a chimeric KCNQ1-KCNQ3 model, with close-up of boxed region. c Representative trace
showing effects at −60mV on KCNQ2/3 current expressed in oocytes during wash-in and washout of 100 µM 3FMSG. d Mean time course of current
increase and decrease during wash-in and washout respectively of 3FMSG (100 µM) expressed as the tau of a single exponential function, quantiﬁed from
traces as in panel (c), n= 3 oocytes (two wash-in/out cycles per oocyte, values averaged for each oocyte). e, f Mean traces (e) and tail current-voltage
relationships (f) for wild-type and arginine-mutant KCNQ2/3 channels traces as indicated in the absence (Ctrl) or presence of 100 µM 3FMSG. RA/RA,
KCNQ2-R213A/KCNQ3-R242A; n= 5–6. g, h Mean traces (g) and tail current-voltage relationships (h) for wild-type and tryptophan-mutant KCNQ2/3
channels traces as indicated in the absence (Control) or presence of 100 µM 3FMSG. WL/WL, KCNQ2-W236L/KCNQ3-W265L; n= 5–6. i 3FMSG dose
responses of wild-type and arginine-mutant KCNQ2/3 channels as in (e, f), quantiﬁed as shift in voltage dependence of activation (ΔV0.5act); n= 5-6. j
3FMSG dose responses of wild-type and tryptophan -mutant KCNQ2/3 channels as in (g, h), quantiﬁed as shift in voltage dependence of activation
(ΔV0.5act); n= 5-6
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Fig. 9 2FPG and 3FMSG KCNQ isoform selectivity arises primarily from functional selectivity. All error bars indicate SEM. a Mean KCNQ2 and KCNQ3*
traces in the absence (Control) versus presence of 2FPG+ 3FMSG, concentrations as indicated (n= 5–6). b Mean KCNQ2 and KCNQ3* raw and
normalized (G/Gmax) tail current versus prepulse voltages for traces as in panel (a) (n= 5–6). “Combo” indicates drug combinations shown with
matching colors in panel (a). c Comparison of effects (expressed as fold-change in tail current versus prepulse voltage) of: 10 µM 2FPG alone (blue, from
data as in Fig. 4) or in combination with 100 µM 3FMSG (green) on KCNQ2 current; 10 µM 3FMSG alone (red, from data as in Fig. 4) or in combination with
100 µM 2FPG (purple) on KCNQ3* current (n= 5–6). d Effects of the drug combinations as in panel (a) on the EM of unclamped oocytes expressing
KCNQ2 or KCNQ3* (n= 5–6). e [3H]GABA binding quantiﬁed in counts per minute (CPM, measured over 30min) to oocytes expressing KCNQ2 (or
injected with water instead of KCNQ2 cRNA, as a control) in the absence or presence of 2FPG or 3FMSG (100 µM) as indicated; n= 18–25. Each point= 1
oocyte. f [3H]GABA binding quantiﬁed in counts per minute (CPM, measured over 30min) to oocytes expressing KCNQ3* (or injected with water instead
of KCNQ3* cRNA, as a control) in the absence or presence of 2FPG or 3FMSG (100 µM) as indicated; n= 15–30. Each point= 1 oocyte. g Exemplar traces
showing KCNQ2 or KCNQ3* currents in response to the voltage protocol (inset) to quantify relative ion permeabilities; reversal potentials measured at
arrow; K+ traces shown. h Effects of 2FPG (10 µM) on relative ion permeabilities of KCNQ2 and KCNQ3*, n= 5. i Effects of 3FMSG (10 µM) on relative ion
permeabilities of KCNQ2 and KCNQ3*, n= 5
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in current at −60 mV (Fig. 10h, i; Supplementary Data 1,
Table 63), similar to the effects we had observed for 10+ 10 µM
(Fig. 10e). We next analyzed the effects on synergy of binding-site
mutations in either KCNQ2 or KCNQ3 within KCNQ2/3
channels. The KCNQ2-W236L mutation eliminated effects of
2FPG but not 3FMSG, and eliminated synergy between 2FPG and
3FMSG. Conversely, the KCNQ3-W265L mutation eliminated
effects of 3FMSG but not 2FPG, and also eliminated synergy
between 2FPG and 3FMSG (Fig. 10h, i; Supplementary Data 1,
Tables 64, 65). The data suggest that synergy between 2FPG and
3FMSG arises from them each preferentially activating a different
isoform within the KCNQ2/3 complex.
We previously found that gabapentin is a potent activator of
KCNQ3 and KCNQ5 but not KCNQ2 channels, and that it also
activates KCNQ2/3 heteromers9. Accordingly, we also found here
that gabapentin synergizes with 2FPG with respect to KCNQ2/3
activation (Fig. 10j–m). The combination of gabapentin and
2FPG (10 µM each) produced a 40-fold increase in KCNQ2/3
current at −60 mV (Fig. 10n), a > 15 mV shift in resting
membrane potential (Fig. 10o) and relatively strong speeding of
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activation and slowing of deactivation (Fig. 10p) (Supplementary
Data 1, Tables 66–68).
Together with the data in Figs. 7–9 and Supplementary Figs 1
and 2 (showing a lack of synergy in homomeric KCNQ2 and
KCNQ3* despite binding of 2FPG and 3FMSG to the
neurotransmitter binding pockets of either isoform), the results
in Fig. 10 demonstrate that combining KCNQ2- and KCNQ3-
preferring compounds such as 2FPG and 3FMSG results in
synergistic activation of KCNQ2/3. The data further demonstrate
that the synergy arises because the combination of different
isoform-preferring compounds leverages the heteromeric channel
composition of KCNQ2/3 channels and the resultant mix of two
different types of binding site.
Discussion
Glycine and glutamate are structurally related to GABA, yet
unlike GABA they do not exhibit negative electrostatic surface
potential centered on the carbonyl group, an established property
of several KCNQ channel openers that activate via KCNQ3-
W26511. Here, we used mapping of electrostatic surface potential
and docking to in silico-engineer a glycine derivative with pre-
dicted KCNQ-opening properties, with the initial hit (4FPG)
resulting from the addition of a ﬂuorophenyl group to the glycine
amide group. Interestingly, 4FPG also activated KCNQ1, which
lacks the S5 tryptophan required for activation by, e.g., retigabine
and GABA, suggesting 4FPG can also activate via the S4/5-
proximal arginine also important for KCNQ2/3 activation
(although we did not pursue KCNQ1 mutagenesis studies herein).
Remarkably, even subtle changes such as moving the ﬂuorine
atom two spaces along in the ring completely altered the KCNQ
isoform selectivity of the glycine derivatives. While we do not yet
understand the channel structural determinants underlying this
selectivity switch, the ﬁnding suggests an avenue in which to
explore future druggable derivatives that lack, e.g., KCNQ4
activity, as we observed for 2FPG and 3FMSG (Fig. 4).
We previously discovered that the heteromeric composition of
KCNQ2/3 channels can be leveraged to potentiate the opening
action of small molecules by combining two or more compounds
with different KCNQ isoform preferences.10. Here, we found that
the principle holds for the glycine-based KCNQ activators, and
also for the combination of KCNQ2-preferring 2FPG and gaba-
pentin, a widely used analgesic that also exhibits anticonvulsant
activity and which we previously found to isoform-selectively
activate KCNQ3 and KCNQ59. The KCNQ2/3 synergy approach
may hold promise as a strategy for avoiding the individual toxi-
cities of some compounds by combining them at lower (poten-
tially safe) concentrations with compounds with alternate KCNQ
isoform preferences, also at lower concentrations.
Interestingly, we also found that, similar to retigabine but not
all KCNQ activators, the maximal efﬁcacy of 2FPG and 3FMSG is
retained in heteromeric KCNQ2/3 channels, despite the insensi-
tivity of KCNQ2 to 3FMSG and of KCNQ3 to 2FPG. This sug-
gests either a dominance of effects of the drug-sensitive subunits
within the complex, or may arise from the domain swapping
nature of KCNQ channels endowing all four repeating units
within the complex with drug sensitivity because each of the
repeating units contains contributions from both KCNQ2
and KCNQ3.
With respect to the predicted deep binding site for the glycine
derivatives, when we mutated the S4-5 arginine in the isoform
that is sensitive to 2FPG (KCNQ2) versus 3FMSG (KCNQ3) to
test the validity of the docking prediction, both in homomeric and
heteromeric channels, we diminished or lost sensitivity and/or
efﬁcacy speciﬁcally to the respective drug, except for in one case
in which the KCNQ2 R213A mutation increased sensitivity of
homomers (and one mutant, KCNQ3*-R242A, was nonfunc-
tional as a homomer). This suggests that the arginine residue
either forms part of the binding site or impacts the way in which
binding is translated into channel activation. This could possibly
be because the drug binding disrupts interaction between the
arginine and the cell membrane, or because mutating the arginine
disrupts its interaction with the cell membrane. However, the
arginine mutants do not greatly alter the voltage dependence of
activation at baseline, suggesting against their mutation drama-
tically altering gating or voltage sensing per se at baseline, at least
in KCNQ2/3 channels. Furthermore, we showed that KCNQ2/3
RA/RA mutant channels no longer bind GABA, and that 2FPG
and 3FMSG displace GABA from wild-type KCNQ2 and
KCNQ3* homomers. These support a model in which the S4-5
Arg is required for binding (either as part of the binding site or
because it inﬂuences the conformation of the binding site) rather
than solely for translating the effects of binding into activation.
In addition, the results of 2FPG and 3FMSG wash-in and
washout studies are consistent with these molecules entering a
deep binding pocket from the external face, and not having to
ﬁrst cross the cell membrane and then access the binding site
from the inner face of the cell membrane. It is technically possible
that one or both of the mutations induce allosteric effects that
disrupt binding of GABA and/or glycine derivatives to a distant
site, or that the S4-5 arginine inﬂuences the conﬁrmation of the
binding pocket but does not form part of it. The simplest
explanation, however, remains that the S5 tryptophan and the S4-
5 arginine line or contribute to the binding site.
There is one additional caveat. KCNQ2/3 α subunits are
expected to exhibit domain-swapping, whereby the VSD of one
subunit aligns with the pore module of the adjoining subunit.
This may potentially result in mixed-isoform binding sites, which
could complicate interpretation of results. This concern is allayed
to a great extent by our ﬁndings for the homomeric mutant
channels (Supplementary Fig. 2). While the results for the
Fig. 10 Leveraging the differential isoform preferences of 2FPG and 3FMSG for synergistic activation of KCNQ2/3. All error bars indicate SEM. a, b Mean
KCNQ2/3 traces at −80 to+ 40mV (a) or solely at −60mV (b) in the absence (Control) versus presence of 2FPG+ 3FMSG (n= 5). c, dMean KCNQ2/
3 tail current (c) and normalized tail currents (G/Gmax) (d) versus prepulse voltage in the absence (black) or presence (orange) of 2FPG+ 3FMSG (each
10 µM) (n= 5). e Mean effect of 2FPG and 3FMSG (10 µM) alone or together on KCNQ2/3 current; n= 5. f Effect of 2FPG+ 3FMSG (each 10 µM) on EM
of unclamped oocytes expressing KCNQ2/3 (n= 5). g Effects of 2FPG+ 3FMSG (each 10 µM) on KCNQ2/3 activation and deactivation rates; n= 5. # P <
0.05. h Mean wild-type (n= 5) or mutant (n= 8) KCNQ2/3 traces in the absence (Control) versus presence of 2FPG and 3FMSG (each 1 µM), separately
or in combination. i Mean raw tail current, normalized tail current (G/Gmax), and current fold-increase versus prepulse voltage for channels indicated in
the absence (black) or presence of 2FPG and 3FMSG (each 1 µM), separately or in combination; n= 5–8. Single-compound fold-effects for wild-type
KCNQ2/3 from Fig. 4. j, k Mean KCNQ2/3 traces at −80 to+ 40mV (j) or solely at −60 mV (k) in the absence (Control) versus presence of 2FPG+
gabapentin (GABAP) (n= 5). l, m Mean KCNQ2/3 tail current (l) and normalized tail currents (G/Gmax) (m) versus prepulse voltage in the absence or
presence of GABAP alone or in combination with 2FPG (each 10 µM) (n= 5). n Mean effect of 2FPG and GABAP (10 µM) alone or in combination on
KCNQ2/3 current versus membrane potential; n= 5. o Effect of GABAP alone or with 2FPG (each 10 µM) on EM of unclamped oocytes expressing
KCNQ2/3 (n= 5). p Effects of 2FPG+GABAP (each 10 µM) on KCNQ2/3 activation and deactivation rates; n= 5. # P < 0.05
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homomers versus the heteromers indicate that neighboring sub-
units certainly have an inﬂuence on the consequences of the
mutations, especially in the case of the S4-5 Arg, the mutant
homomeric channel data still support a role for the S4-5 Arg and
the S5 W in mediating modulation by the glycine derivatives.
Based on the data herein, we feel secure in stating that 2FPG and
3FMSG can each bind to both homomeric KCNQ2 and KCNQ3*
channels, and that their isoform selectivity arises predominantly
from the selectivity of their functional effects, and to a lesser
extent their binding selectivity (the latter occurs, but cannot
explain the lack of effects of 2FPG and 3FMSG on their non-
preferred isoform even at high concentrations). Further, our data
conclusively demonstrate that 2FPG and 3FMSG (or gabapentin)
synergistically activate KCNQ2/3 channels by leveraging their
isoform selectivity (both binding preference and functional
selectivity) and the heteromeric composition of these channels.
The screening approach we used will be applicable to many
other classes of small molecules with respect to predicting KCNQ
channel activation, i.e., identify those compounds with the pre-
ferred chemical properties, dock to ﬁlter out predicted non-
binders and then validate in vitro. The docking program was able
to correctly predict lack of glycine activity and also predicted
binding of 2FPG, 4FPG and 3FMSG, but at this stage the model
and/or docking program we use are not sophisticated enough to
predict KCNQ isoform selectivity. While it is relatively trivial,
once predicted KCNQ activity is identiﬁed, to test each of the
KCNQ homomers for sensitivity in vitro, an accurate system in
which isoform speciﬁcity could be used as a ﬁlter before in vitro
screening, would be beneﬁcial. With relatively few in silico
screening steps and sufﬁcient computing power, it may therefore
be possible in the future to identify from massive commercially
available chemical libraries safe, potent KCNQ openers that lack
KCNQ4 opening activity.
Methods
Channel subunit cRNA preparation and Xenopus laevis oocyte injection. We
generated cRNA transcripts encoding human KCNQ1, KCNQ2, KCNQ3, KCNQ4,
KCNQ5 or GLRA1 (NM_001146040) (GenScript, Piscataway, NJ, USA) by in vitro
transcription using the T7 polymerase mMessage mMachine kit (Thermo Fisher
Scientiﬁc), after vector linearization, from cDNA sub-cloned into plasmids incor-
porating Xenopus laevis β-globin 5′ and 3′ UTRs ﬂanking the coding region to
enhance translation and cRNA stability. We quantiﬁed cRNA by spectro-
photometry. We generated mutant KCNQ2 and KCNQ3 cDNAs by site-directed
mutagenesis using a QuikChange kit (Stratagene, San Diego, CA) and prepared the
corresponding cRNAs as above. We injected defolliculated stage V and VI Xenopus
laevis oocytes (Ecocyte Bioscience, Austin, TX and Xenoocyte, Dexter, MI) with
KCNQ channel α subunit (5-20 ng) or GLRA1 (20 ng) cRNAs. We incubated the
oocytes at 16 °C in Barth’s saline solution (Ecocyte Bioscience) containing peni-
cillin and streptomycin, with daily washing, for 2–5 days prior to two-electrode
voltage-clamp (TEVC) recording.
Two-electrode voltage clamp (TEVC). We performed TEVC at room tempera-
ture using an OC-725C ampliﬁer (Warner Instruments, Hamden, CT) and
pClamp10 software (Molecular Devices, Sunnyvale, CA) 2–5 days after cRNA
injection as described in the section above. For recording, oocytes were placed in a
small-volume oocyte bath (Warner) and viewed them with a dissection microscope.
Chemicals were sourced from Sigma, Matrix Scientiﬁc and Santa Cruz. (2-ﬂuor-
ophenyl) glycine, N-(3-ﬂuorophenyl)-N-(methylsulfonyl) glycine and 2-(Tri-
ﬂuoromethyl)-DL-phenylglycine were each solubilized in bath solution at a stock
concentration of 10 mM; 2-amino-2-(4ﬂuorophenyl) acetic acid and 4-(tri-
ﬂuoromethyl)-L-phenylglycine were solubilized in 1 M hydrochloric acid at a stock
concentration of 10 mM. All stock solutions were diluted in bath solution on the
day of experiments. KCNQ2/3 channel activation was screened for using either 30
µM or 100 µM concentrations of each of the six compounds, then dose responses
were conducted as appropriate. Bath solution was (in mM): 96 NaCl, 4 KCl, 1
MgCl2, 1 CaCl2, 10 HEPES (pH 7.6). Compounds were introduced into the oocyte
recording bath by gravity perfusion at a constant ﬂow of 1 ml per minute for 3 min
prior to recording. Pipettes were of 1–2MΩ resistance when ﬁlled with 3 M KCl.
Currents were recorded in response to voltage pulses between −120 or −80 mV
and+ 40 mV at 20 mV intervals from a holding potential of −80 mV, to yield
current-voltage relationships, current magnitude, and for quantifying activation
rate. We analyzed data using Clampﬁt (Molecular Devices) and Graphpad Prism
software (GraphPad, San Diego, CA, USA); values are stated as mean ± SEM. We
plotted raw or normalized tail currents versus prepulse voltage and ﬁtted with a
single Boltzmann function:
g ¼ ðA1  A2Þ
1þ exp ðV1
2
 VÞ=VS
  
þ A2
; ð1Þ
where g is the normalized tail conductance, A1 is the initial value at −∞, A2 is the
ﬁnal value at +∞, V1/2 is the half-maximal voltage of activation and Vs the slope
factor. Activation, deactivation, wash-in and washout kinetics were ﬁtted with
single exponential functions to yield a τ value.
Relative permeability calculations. According to the Goldman–Hodgkin–Katz
(GHK) voltage equation:
Erev ¼
RT=F lnðPK½KþO þ PNa½NaO þ PCl½CliÞ
ðPK½Kþi þ PNa½Nai þ PCl½CloÞ
; ð2Þ
where Erev is the absolute reversal potential and P is permeability. This permits
calculation of the relative permeability of each ion if concentrations on either side
of the membrane are known. A modiﬁed version of this equation was used here to
determine relative permeability of two ions in a system in which only the extra-
cellular ion concentration was known. Thus, relative permeability of Rb+, Cs+, and
Na+ compared to K+ ions was calculated for KCNQ2 and KCNQ3* by plotting the
I/V relationships for each channel with each extracellular ion (100 mM) (using the
voltage protocol shown in Fig. 9g) and comparing them to that with 100 mM
extracellular K+ ion to yield a change in reversal potential (ΔErev) for each ion
compared to that of K+. Permeability ratios for each ion (X) compared to K+ were
then calculated as
ΔErev ¼ Erev;X  Erev;K ¼ ln
PX
PK
: ð3Þ
These values were then compared for each channel against Rb+, Cs+, Na+, and
K+ containing 100 µM 2FPG or 100 µM 3FMSG and statistical signiﬁcance was
assessed using ANOVA.
GABA and glycine radioligand binding studies. Each group of oocytes was
placed in a round-bottomed, 15-ml Falcon tube, washed with ND96, and then
resuspended in ND96 containing 10 µM γ-[2,3-3H(N)]-aminobutyric acid (3H-
GABA) or [2-3H]-Glycine (Perkin Elmer, Waltham, MA) at 25-45 Ci/mMol spe-
ciﬁc activity (1 µM concentration) either alone, or with 100 µM 2FPG, 3FMSG or
cold glycine for a 30 min incubation at room temperature. Oocytes were then
washed four times in 16 °C ND96, transferred to individual wells in a 96 well plate
and lysed in 0.2% SDS in ND96. Each oocyte lysate was transferred to a scintil-
lation vial containing 5 ml Cytoscint scintillation cocktail ﬂuid (MP Biomedicals,
Santa Ana, CA). Vials were capped, shaken, and then allowed to sit at room
temperature for at least 30 min before scintillation counting in a Beckmann Coulter
LS6500 liquid scintillation counter.
Chemical structures and silico docking. We plotted and viewed chemical
structures and electrostatic surface potentials using Jmol, an open-source Java
viewer for chemical structures in 3D: http://jmol.org/. For in silico ligand docking
predictions of binding to KCNQ2-5 channels, the Xenopus laevis KCNQ1 cryoEM
structure (PDB 5VMS)12 was ﬁrst altered to incorporate KCNQ3/KCNQ5 residues
known to be important for retigabine and ML-213 binding, and their immediate
neighbors, followed by energy minimization as we previously described8 using the
GROMOS 43B1 force ﬁeld19 in DeepView20. We performed unguided docking of
the compounds described in the manuscript, to predict potential binding sites,
using SwissDock with CHARMM forceﬁelds21,22.
Statistics and reproducibility. All values are expressed as mean ± SEM. One-way
ANOVA was applied for the majority of tests; if multiple comparisons were per-
formed, a post hoc Tukey’s HSD test was performed following ANOVA. Statistical
signiﬁcance was deﬁned as P < 0.05. Oocyte experiments were each performed on
at least two separate batches of oocytes to conﬁrm reproducibility.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The raw datasets generated during the current study are available from the
corresponding author on reasonable request. The source data underlying plots is
presented in Supplementary Data 1.
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